Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Investor Presentation (March 2022)
22 slides from Botanix Pharmaceuticals's investor presentation, Mar 14, 2022
Slide 1: Investor Presentation: Key highlights
14 March 2022 Investor Presentation Key highlights For personal use only • Release of updated corporate presentation for Botanix’s investor roadshow this week and the Switzer Small and Micro cap Conference on the 23rd of March • The presentation includes updates on the Company’s clinical pipeline wi
Slide 2: Cautionary Note on Forward-Looking Statements
General enquiries Investor enquiries Media enquiries Corporate Communications Hannah Howlett Haley Chartres Botanix Pharmaceuticals WE Communications H^CK P: +61 8 6555 2945 P: +61 450 648 064 P: +61 423 139 163 investors@botanixpharma.com hhowlett@we-worldwide.com haley@hck.digital For personal use
Slide 3: Botanix Overview
For personal use only Operations: 3602 Horizon Drive, Suite 160 Botanix Overview King of Prussia PA 19041 Corporate Office: March 2022 Level 1, 50 Angove Street North Perth W. Australia 6006 www.botanixpharma.com
Slide 4: US focused clinical stage dermatology company
US focused clinical stage dermatology company Targeting billion-dollar markets with novel products For personal use only Pharmaceutical focus New treatments for common skin diseases (such as rosacea and acne), and life threatening bacterial infections Topically driven Dermatologists prefer creams an
Slide 5: Corporate Overview
Corporate Corporate Overview For personal use only ASX: BOT Trading Information Share price performance (last 6 months) Share price A$0.061 Price (A$) Volume (m) $0.16 0.0 6-month low / high A$0.061/0.115 Shares outstanding 973,142,074 0.0 Market Capitalisation A$59.36 $0.12 Cash (31 Dec 2021) A$ 16
Slide 6: Botanix: World Class Board and Management team
World class team Botanix: World Class Board and Management team For personal use only Board of Directors Vince Ippolito Matt Callahan Dr Bill Bosch Dr Stewart Washer President and Executive Chairman Executive Director Executive Director Director COO of Anacor and Medicis with 17 Serial founder a
Slide 7: Botanix team has led multiple successful product development campaigns and launches
World class team Botanix team has led multiple successful product development campaigns and launches For personal use only 5 www.botanixpharma.com
Slide 8: Global dermatology market is worth more than $33 billion
Significant markets Global dermatology market is worth more than $33 billion - with little recent innovation For personal use only Global dermatology market 1 More than 3,000 types of dermatological conditions exist, ranging in severity and clinical presentation $40 CAGR: 7.7% Approximately 1/3
Slide 9: Advanced late-stage pipeline
Pharmaceutical focus Advanced late-stage pipeline For personal use only Ph 1 Ph 1b Ph 2 Ph 3 Status Positive Phase 2a results BTX 1801 announced, Phase 2b start Antimicrobial end 1Q 2022 BTX 1702 Underway – enrolment Rosacea complete by mid 2022 BTX 1503 Planning underway for Phase 3 Acne clinical s
Slide 10: Target markets with significant annual revenues & unmet needs
Significant markets Target markets with significant annual revenues & unmet needs For personal use only Rosacea Antimicrobial 16M patients 100k patients Specialised / $0.5bn Dermatologists $1.9bn Sales 2 Sales 1 US Prescriber Atopic Acne Base Dermatitis 50M patients 75M patients $5.1bn Sales 3 Gener
Slide 11: Permetrex skin delivery technology fuels the pipeline
Topically driven PermetrexTM skin delivery technology fuels the pipeline Delivers high doses of drug into the layers of the skin without using irritating permeation For personal use only enhancers, preservatives, or alcohol / petroleum derivatives 1. Initial application 2. Evaporation of solvent 3.
Slide 12: Dermatology programs
Dermatology programs For personal use only 10 www.botanixpharma.com
Slide 13: BTX 1702: high impact of rosacea on patients and significant market opportunity
Dermatology BTX 1702: high impact of rosacea on patients and significant market opportunity For personal use only A rapidly growing market: Rosacea market projected to Papulopustular rosacea is a grow to US$2.6bn by 20253 highly visible chronic skin disease characterised by US$2.6bn redness (inflam
Slide 14: BTX 1702: Rosacea Phase 1b/2 study nearing completion
Dermatology BTX 1702: Rosacea Phase 1b/2 study nearing completion Randomised controlled study in patients for 8 weeks For personal use only Study design Study designed to enable Three dose groups, ~120 patients: Endpoints: increased data capture & – BTX 1702 high dose - twice daily: 40 patient
Slide 15: Atopic dermatitis – chronic inflammatory disease for both canines and humans
Dermatology Atopic dermatitis – chronic inflammatory disease for both canines and humans For personal use only Canines naturally develop a form of dermatitis that is extremely similar to human dermatitis4 Dogs and humans with dermatitis also have similar problems with skin barrier function – whi
Slide 16: BTX 1204A: Atopic dermatitis development strategy
Dermatology BTX 1204A: Atopic dermatitis development strategy Larger POC canine study underway1, will inform licensing in animal health & potential re-launch of For personal use only late-stage P2b clinical program in 2022 Proof of Concept Canine Study Planned pathway to approval Parameters Four d
Slide 17: BTX 1503: Acne in preparation for Phase 3 and future filing
Dermatology BTX 1503: Acne in preparation for Phase 3 and future filing Completion of Rosacea BTX 1702 study (with higher dosing) will inform final design for P3 Acne study For personal use only Study update Sizable acne prescription market End of Phase 2 meeting with FDA successfully 22m total pr
Slide 18: Anti-microbial development update: BTX 1801
Anti-microbial development update For personal use only BTX 1801
Slide 19: BTX 1801: Demonstrated clinical efficacy vs S. aureus in Phase 2a study
Antimicrobial BTX 1801: Demonstrated clinical efficacy vs S. aureus in Phase 2a study For personal use only Staphylococcus aureus (S. aureus or ‘staph’) is a common bacterium that lives on skin and in nasal passages. It can cause skin infection and serious or life- threatening blood stream infection
Slide 20: BTX 1801: Haemodialysis patients with central venous catheters at risk of bloodstream infections
Antimicrobial BTX 1801: Haemodialysis patients with central venous catheters at risk of bloodstream infections For personal use only Haemodialysis Replicates the functions of the kidneys in patients with kidney failure, by using a machine to filter and clean the blood Rationale for Infection is
Slide 21: Executing on key clinical milestones
Corporate Executing on key clinical milestones For personal use only Antimicrobial: BTX 1801 Phase 2b study Positive Phase 2a results announced, Phase 2b study start end 1Q 2022 Rosacea: BTX 1702 Phase 1b/2 study Targeting full enrolment mid 2022, with data 3Q 2022 Acne: BTX 1503 for Phase 3 c
Slide 22: Disclaimer
DISCLAIMER For personal use only Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,”
Botanix Pharmaceuticals — Investor Presentation (March 2022) on 6ix